You are here
P&T® Journal contents for June 2008
Letter to the Editor
Advances in medical technologies have led to improved diagnoses and treatments, but medical devices do not always undergo the rigorous review process that is applied to drugs. To control costs, some health care facilities are becoming more selective in how they evaluate new devices.
Because of the complex process involved in adding bar codes to all drug packages in order to prevent fraud, it might be difficult for pharmacies to fulfill the requirements of the e-Pedigree law, even by the target date of 2011.
Medically accepted off-label uses of azacitidine (Vidaza) and a new indication for lubiprostone (Amitiza) are discussed.
Presentations cover iloperidone (Fanapta) for schizophrenia, asenapine for bipolar disorder, and virtual reality sessions for patients with post-traumatic stress disorder.
According to a 2007 report, most dermatologists predicted that biologic therapies would be used more frequently in the next year; did not follow formularies they considered too restrictive; and expressed concern about denials of paper claims and reimbursements for surgical procedures combined with office visits.